F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
https://www.nytimes.com/2026/08/26/science/pancreatic-cancer-daraxonrasib-approval.html